Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.685 USD | +10.04% | +45.14% | +26.06% |
May. 21 | Erasca Closes Oversubscribed Share Offering to Raise $184 Million | MT |
May. 17 | Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.06% | 697M | |
+63.51% | 62.59B | |
-1.15% | 41.18B | |
+44.76% | 40.29B | |
-8.29% | 27.9B | |
+13.09% | 26.21B | |
-21.51% | 19.09B | |
+5.43% | 13.08B | |
+25.21% | 12.26B | |
+28.39% | 12.05B |
- Stock Market
- Equities
- ERAS Stock
- News Erasca, Inc.
- Erasca Doses First Patient in Trial Assessing Naporafenib Plus Trametinib in Patients With RAS Q61X Solid Tumors